Archive

Reuters blog archive

from Breakingviews:

Valeant urges $54 bln deal with carrot, two sticks

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant is pushing its $54 billion deal with the help of a carrot and two sticks. The pharmaceutical group raised its offer for Allergan again on Friday, on the condition that the board of its target cooperates. Meanwhile hedge fund boss Bill Ackman on Monday threatened to unseat six directors – and Valeant could yet decide to go fully hostile. But questions over Valeant’s own stock remain its biggest weakness.

Allergan previously questioned Valeant’s accounting and compared its acquisitive rollup strategy to that which felled Tyco International under Dennis Kozlowski. The aggressive counterattack put Valeant on the back foot after an earlier rather feeble-looking increase in its offer. The latest more significant boost, by another 8 percent-plus, puts the heat back on Allergan’s board and Ackman’s move adds to the pressure to be seen to take Valeant seriously.

The new offer works out to about $181 per Allergan share, of which $72 is in cash. The extra money on offer is all in the cash component. That reflects the fact that Allergan’s managers aren’t the only people worried about the quality of the paper on offer.

from Breakingviews:

Glaxo wrestles with its past

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Investors keep taking hits on GlaxoSmithKline. The pharmaceutical group’s stock price has fallen nearly 10 percent in the last year on the back of weaker sales and bribery accusations in China. News of a criminal investigation in the United Kingdom knocked almost $2 billion of its market capitalisation on Wednesday morning.

from Breakingviews:

Failed bid would leave Astra under pressure

By Chris Hughes
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The likely failure of U.S. drugmaker Pfizer’s $119 billion bid for AstraZeneca, which was due to lapse on May 26, would leave the frustrated buyer no worse off. But the target has much to prove. Some of its shareholders welcomed a possible takeover - and could again.

from Breakingviews:

Astra-Pfizer needs a fresh start later in the year

By Chris Hughes
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

AstraZeneca should not reengage with Pfizer in the dying days of the takeover timetable. Talks now would either be fruitless or delay a proper restart later.

from Breakingviews:

Loophole offers Pfizer risky way back into AZ deal

By Chris Hughes

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer has a risky way back into a deal with AstraZeneca. An apparent loophole in Britain’s takeover code means the U.S. pharma group could offer the 58.85 pounds-a-share demanded by Astra for a recommendation, even after declaring that the earlier 55 pounds-a-share pitch was “final.”

from Breakingviews:

Where should AstraZeneca shares be trading?

By Chris Hughes
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Investors are putting a lot of faith in Pfizer succeeding in its $100 billion-plus quest to acquire UK pharmaceuticals rival AstraZeneca. The right price for the target’s share price can be seen as the weighted average of two possible outcomes – a sale to Pfizer or a standalone future. A new Breakingviews calculator shows why the market seems to think a transaction will probably happen.

from Breakingviews:

Pfizer unlikely to avoid China anti-trust therapy

By Ethan Bilby

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The chance to vet Pfizer’s $106 billion offer for rival drug-maker AstraZeneca looks too good to pass up for China’s competition watchdog. Pfizer should brace for some antitrust therapy, though getting Astra’s board on-side first may help.

from Breakingviews:

Pfizer yet to land knockout blow on Astra

By Neil Unmack 

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer’s courtship of AstraZeneca looks like a hate-hate relationship. In January, UK pharmaceuticals group AstraZeneca viewed its U.S. larger rival’s proposal of 46.61 pounds a share as too low on cash, too risky, and too cheap to even talk about. Pfizer’s latest proposal, an attempt to get Astra to begin friendly talks, hasn’t moved the needle much.

from Breakingviews:

Astra has small tactical advantage over Pfizer

By Christopher Hughes and Neil Unmack
The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

Time often benefits bidders rather than targets – that’s why U.S.-based food group Kraft left Cadbury flailing for months after making a takeover approach for its UK competitor. But the dynamics of Pfizer’s interest in rival pharmaceuticals group AstraZeneca are unusual. Pfizer has good reason to seek a quick, agreed deal.

from Breakingviews:

Pfizer tax arbitrage will hasten more deals

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer’s $99 billion tax arbitrage bid will encourage copycats. The biggest charm of the U.S. drug giant’s offer for AstraZeneca of the UK lies in switching to a lower-tax domicile. The latest and largest such deal to hit the headlines raises the odds Congress will tighten rules – but not yet.

  •